Abstract
We appreciate the comments from Theodorakis (1) in response to our findings of reduced glucagon-like peptide 1 (GLP-1) release in prediabetes, screen-detected type 2 diabetes, and obesity (2). Theodorakis suggests that participants with screen-detected diabetes in the ADDITION-PRO study may have had long-standing diabetes, which could then explain why findings on GLP-1 release in participants with type 2 diabetes in the ADDITION-PRO study and the Baltimore Longitudinal Study of Aging (BLSA) point in different directions. The ADDITION-PRO study performed in 2009–2011 was originally designed to quantify diabetes progression rates, examine early markers of micro- and macrovascular diabetes complications, and understand the related mechanisms …
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
